Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

无容量 易普利姆玛 医学 内科学 耐火材料(行星科学) 胰腺癌 肿瘤科 随机对照试验 放射治疗 放射外科 临床研究阶段 立体定向放射治疗 癌症 临床试验 免疫疗法 物理 天体生物学
作者
Inna M. Chen,Julia S. Johansen,Susann Theile,Jessica Xin Hjaltelin,Sif I. Novitski,Søren Brunak,Jane Preuss Hasselby,Gro Linno Willemoe,Torben Lorentzen,Kasper Madsen,Benny Vittrup Jensen,Eva E. Wilken,Poul Geertsen,C.F. Behrens,Christian Nolsøe,Kirstine Lintrup Hermann,Inge Marie Svane,Dorte Nielsen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (27): 3180-3189 被引量:107
标识
DOI:10.1200/jco.21.02511
摘要

PURPOSE To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy (SBRT) in patients with refractory metastatic pancreatic cancer (mPC). METHODS Between November 2016 and December 2019, patients with refractory mPC were randomly assigned 1:1 to SBRT of 15 Gy with nivolumab or nivolumab/ipilimumab stratified by performance status (ClinicalTrials.gov identifier: NCT02866383 ). The primary end point was the clinical benefit rate (CBR), defined as the percentage of patients with complete or partial response (PR) or stable disease, according to RECIST 1.1. Simon's 2-stage phase II optimal design was used independently for both arms, with CBR determining expansion to the second stage. Secondary end points included safety, response rate, duration of response, progression-free survival, and overall survival. Exploratory analyses included biomarkers related to the benefits. RESULTS Eighty-four patients (41 SBRT/nivolumab and 43 SBRT/nivolumab/ipilimumab) received at least one dose of study treatment. CBR was 17.1% (8.0 to 30.6) for patients receiving SBRT/nivolumab and 37.2% (24.0 to 52.1) for SBRT/nivolumab/ipilimumab. PR was observed in one patient receiving SBRT/nivolumab and lasted for 4.6 months. Six patients receiving SBRT/nivolumab/ipilimumab achieved a PR with a median duration of response of 5.4 months (4.2 to not reached). Grade 3 or higher treatment-related adverse events occurred in 10 (24.4%) and 13 (30.2%) patients in the SBRT/nivolumab and SBRT/nivolumab/ipilimumab groups, respectively. Programmed cell death ligand-1 expression by tumor proportion score or combined positivity score of ≥ 1% was not associated with clinical benefits. On-treatment decreased serum interleukin-6, interleukin-8, and C-reactive protein levels were associated with better overall survival. CONCLUSION Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with SBRT/nivolumab/ipilimumab in patients with refractory mPC. However, the contribution from SBRT is unknown. Further studies are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LI发布了新的文献求助10
1秒前
顺心秋天完成签到 ,获得积分10
1秒前
赘婿的应助被霍则风采纳,获得10
1秒前
天天快乐的应助被Hang采纳,获得10
1秒前
YD发布了新的文献求助10
2秒前
小蒋完成签到,获得积分10
3秒前
徐小薛完成签到,获得积分10
3秒前
4秒前
Hannah完成签到 ,获得积分10
4秒前
小鱼发布了新的文献求助10
4秒前
oceanL完成签到,获得积分10
4秒前
5秒前
5秒前
8秒前
8秒前
8秒前
李健的应助被YD采纳,获得10
9秒前
diu发布了新的文献求助30
9秒前
aa完成签到,获得积分10
9秒前
所所的应助被Reean采纳,获得10
9秒前
diqiuqiuzhang发布了新的文献求助30
9秒前
skp完成签到,获得积分10
11秒前
滴滴答答发布了新的文献求助10
11秒前
huiyouzhiyu完成签到,获得积分10
11秒前
体力里发布了新的文献求助10
12秒前
12秒前
独特的依云完成签到 ,获得积分10
13秒前
ROY完成签到,获得积分10
13秒前
学术饕餮发布了新的文献求助10
13秒前
mole7777完成签到 ,获得积分10
13秒前
我在庞贝完成签到,获得积分10
14秒前
14秒前
辣椒完成签到,获得积分10
15秒前
无极微光的应助被邓111111采纳,获得20
15秒前
啵子发布了新的文献求助10
16秒前
李爱国的应助被Z20251040501采纳,获得10
16秒前
16秒前
wanci的应助被太空的脚步采纳,获得10
16秒前
16秒前
YoPbsn发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187918
求助须知:如何正确求助?哪些是违规求助? 9575850
关于积分的说明 21843829
捐赠科研通 7785760
什么是DOI,文献DOI怎么找? 3435128
关于科研通互助平台的介绍 2559501
邀请新用户注册赠送积分活动 2482027